Literature DB >> 8470123

The nongenotoxic hepatocarcinogen Wy-14,643 is an uncoupler of oxidative phosphorylation in vivo.

B J Keller1, B U Bradford, D S Marsman, R C Cattley, J A Popp, H K Bojes, R G Thurman.   

Abstract

Wy-14,643 is a potent nongenotoxic hepatic carcinogen and peroxisome proliferator in rodents; however, the mechanism by which it causes tumors remains unknown. In previous work it was demonstrated that Wy-14,643 caused a dose-dependent uncoupling of oxidative phosphorylation (half-maximal effect = 100 microM) in isolated mitochondria (Keller et al., 1992, Biochim. Biophys. Acta, 1162, 237-244); therefore, the purpose of this study was to determine if uncoupling occurred in vivo under conditions which lead ultimately to tumors. Rats were fed Wy-14,643 (0.1%) in ground laboratory chow for 1, 21, 75, and 105 days. As expected, activity of the peroxisomal marker enzyme, acyl-CoA oxidase, was increased about eightfold in liver homogenates during the first 3 weeks of treatment, confirming the induction of peroxisomes. Basal rates of oxygen uptake by the perfused liver were increased significantly by Wy-14,643 treatment at all time points studied, consistent with the hypothesis that oxidative phosphorylation was uncoupled. Basal rates of oxygen uptake of about 130 mumol/g/hr were increased by over 20 mumol/g/hr in rats fed Wy-14,643 in their diet for 10 weeks. Concomitantly, rates of urea synthesis from ammonia, a process highly dependent on ATP supply, were reduced significantly in the perfused liver from 104 mumol/g/hr in control livers to 13 mumol/g/hr in livers from rats treated with Wy-14,643 for 75 days. Taken together, these data indicate that energy supply is disrupted in vivo due to uncoupling of oxidative phosphorylation by Wy-14,643.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8470123     DOI: 10.1006/taap.1993.1043

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  5 in total

1.  Suppression of agonist induced Ca2+ oscillations in cultured hepatocytes by nafenopin: possible involvement of protein kinase C.

Authors:  E Leibold; A Stampfl; L R Schwarz
Journal:  Arch Toxicol       Date:  1996       Impact factor: 5.153

2.  Chronic treatment with the peroxisome proliferator-activated receptor alpha agonist Wy-14,643 attenuates myocardial respiratory capacity and contractile function.

Authors:  Makhosazane Zungu; Martin E Young; William C Stanley; M Faadiel Essop
Journal:  Mol Cell Biochem       Date:  2009-04-10       Impact factor: 3.396

Review 3.  PPARs and the cardiovascular system.

Authors:  Milton Hamblin; Lin Chang; Yanbo Fan; Jifeng Zhang; Y Eugene Chen
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

4.  Protective Effects of Peroxisome Proliferator-Activated Receptor-α Agonist, Wy14643, on Hypoxia/Reoxygenation Injury in Primary Rat Hepatocytes.

Authors:  Ke Chen; Yuan-Hai Li; Si-Qi Xu; Sheng-Hong Hu; Lei Zhang
Journal:  PPAR Res       Date:  2011-10-09       Impact factor: 4.964

5.  Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist.

Authors:  G Wölkart; A Schrammel; K Dörffel; G Haemmerle; R Zechner; B Mayer
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.